2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
Loading...
Date
Authors
Herrstedt, J.
Clark-Snow, R.
Ruhlmann, C.H.
Molassiotis, A.
Olver, I.
Rapoport, Bernardo Leon
Aapro, M.
Dennis, K.
Hesketh, P.J.
Navari, R.M.
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Nausea and vomiting are still considered to be two of the most troublesome adverse events (AEs) for patients treated with antineoplastic therapy. To optimise the utility of available antiemetic prophylaxis, updated reviews of the relevant literature and evidence-based guideline recommendations are crucial.
The European Society for Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) completed the fourth Consensus Conference on Antiemetics for the prevention of nausea and vomiting in patients with cancer in Copenhagen in June 2015. This article is an update of the 2015 guidelines.
Description
Keywords
Prevention, Nausea, Vomiting, MASCC–ESMO clinical practice guideline, Radiotherapy, Chemotherapy, European Society for Medical Oncology (ESMO), Multinational Association of Supportive Care in Cancer (MASCC), SDG-03: Good health and well-being
Sustainable Development Goals
SDG-03:Good heatlh and well-being
Citation
Herrstedt, J., Clark-Snow, R., Ruhlmann, C.H. et al. 2024, '2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting', ESMO Open, vol. 9, no. 2, art. 102195, pp. 1-18, doi : 10.1016/j.esmoop.2023.102195.